Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Protein Therapies
VistaGen Awarded $1.2 Million from NIH for Development of AV-101 for Neuropathic Pain, Parkinson's Disease and Epilepsy
November 22nd, 2007
VistaGen Therapeutics, Inc., a platform-enabled biopharmaceutical company applying embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders, announced that it has been awarded $1.2 million in funding from the National Institutes of Health (NIH) to support final preparation and filing of the Company's AV-101 Investigational New Drug application with the Food and Drug Administration in early 2008. The award is the final phase of an aggregate of $4.3 million of grant support from the National Institute of Neurological Disorders and Stroke (NINDS), a division of the NIH, for...
Source: Genetics & Environmental Business Week (2007-11-22)
|
